masivet
ab science s.a. - masitinib mesilate - antinavikiniai vaistai - Šunys - nepakartojamų šunų masto ląstelių navikų (2 arba 3 laipsnio) gydymas, patvirtintas mutavusių c-kit tirozino kinazės receptorių.
alsitek
ab science - masitinib mesilate - amiotrofinė šoninė sklerozė - antinavikiniai vaistai - gydymo šonine amiotrofine skleroze.
masipro
ab science - masitinib mesilate - mastocitozė - antinavikiniai vaistai - gydymo mastocytosis.
masiviera
ab science - masitinibas - kasos navikai - baltymų kinazės inhibitoriai - gydymas ne resectable lokaliai išplitusio arba metastazavusio kasos vėžys.
masican
masitinibas - virškinimo trakto stromos navikai - baltymų kinazės inhibitoriai - gydymo unresectable ir/arba metastazavusio piktybinių virškinimo trakto stromos navikas (gist).
dasatinib accord
accord healthcare s.l.u. - dasatinibas - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antinavikiniai vaistai - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinibas - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antinavikiniai vaistai - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib sandoz
sandoz d.d. - dazatinibas - plėvele dengtos tabletės - 20 mg - dasatinib
dasatinib sandoz
sandoz d.d. - dazatinibas - plėvele dengtos tabletės - 50 mg - dasatinib
dasatinib sandoz
sandoz d.d. - dazatinibas - plėvele dengtos tabletės - 70 mg - dasatinib